Status
Conditions
About
The purpose of this study is to evaluate, in patients in at least the second protease inhibitor (PI) line, the virological failures under Kaletra® and their consequences on protease and reverse transcriptase genotypes
Full description
The purpose of this study is to evaluate, in patients in at least the second PI line, the virological failures under Kaletra® and their consequences on protease and reverse transcriptase genotypes:
EOLE is a prospective, multicentre observation study offered to French virology laboratories and involving clinical teams .
It is a transversal study with retrospective data collection for patients meeting the study criteria (virological failure under Kaletra® after at least first line PI treatment).
The study comprises two enrolment periods, separated by an interval of one year, over a period ranging from 2007 to 2011. During this period, virological failures under Kaletra® are identified. For each period, the virologists collect data only from the moment when virological failure under Kaletra® is identified.
The first wave of data collection is now completed and occurred from December 5, 2007 to July 03, 2009.
It is not planned to collect follow-up data in connection with alternative treatment with other antiretrovirals after failure under Kaletra®.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Therapeutic failure is defined by a viral load> 50 copies/ml after at least three months' treatment with an ARV combination containing Kaletra®, always provided that genotyping is possible .
Exclusion criteria
94 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal